astrazeneca mesothelioma

Web results
AstraZeneca reports top-line result of tremelimumab monotherapy trial ...
https://www.astrazeneca.com/.../astrazeneca-reports-top-line-result-of-tremelimumab-...



Feb 28, 2016 - Trial did not meet primary endpoint of improving overall survival in challenging to treatmesothelioma patients with no currently approved ...
AstraZeneca's Mesothelioma Therapy Tremelimumab Disappoints in ...
https://mesotheliomaresearchnews.com/.../mesothelioma-therapy-tremelimumab-disap...


Jul 28, 2017 - A Phase 2b clinical trial of AstraZeneca’s mesothelioma therapy tremelimumab showed no significant difference in survival times between treated and untreated patients. ... Results of the international study, which covered 571 patients with peritoneal or pleural malignant ...
Tremelimumab as second-line or third-line treatment in relapsed ...
https://www.ncbi.nlm.nih.gov/pubmed/28729154by M Maio - ‎2017 - ‎Cited by 48 - ‎Related articlesJul 17, 2017 - (12)Mesothelioma Unit-Medical Oncology Department, SS Antonio e Biagio General ... (15)AstraZeneca, Alderley Park, Macclesfield, UK.

FDA Approval of Drugs Valuable In Mesothelioma Care
https://www.mesotheliomahelp.org/fda-continues-approval-immunotherapy-drugs-val...


Aug 15, 2017 - This approval brings one more immunotherapy option to lung cancer and mesotheliomapatients, and another approval for AstraZeneca in its ...
Durvalumab (Imfinzi) - Emerging Mesothelioma Immunotherapy
https://www.asbestos.com › Treatment › A Search for the Cure › Immunotherapy


It is marketed under the brand name Imfinzi and manufactured by AstraZeneca. Durvalumab helps the immune system fight cancer, and clinical trials are testing ...

Tremelimumab Failed to Extend Mesothelioma Survival Rates
https://www.asbestos.com/.../astrazeneca-stops-tremelimumab-mesothelioma-clinical-tr...



Mar 1, 2016 - Mesothelioma is a rare and aggressive cancer caused primarily by ... AstraZeneca'sannouncement Monday stems from the clinical trial ...
AstraZeneca Archives » Mesothelioma Applied Research Foundation
https://www.curemeso.org/tag/astrazeneca/


The Meso Foundation released a statement from its executive director, Mary Hesdorffer, APRN, aboutAstraZeneca's tremelimumab trial for mesothelioma.
Closely watched AstraZeneca cancer drug fails in mesothelioma
www.reuters.com/...astrazeneca.../closely-watched-astrazeneca-cancer-drug-fails-in-meso...Feb 29, 2016 - LONDON (Reuters) - A closely watched AstraZeneca drug did not extend lives of patients with the rare cancer mesothelioma when given on its ...
Tremelimumab Misses OS Endpoint in Phase IIb Mesothelioma Trial
https://www.onclive.com/.../tremelimumab-misses-os-endpoint-in-phase-iib-mesotheli...


Mar 1, 2016 - Tremelimumab Misses OS Endpoint in Phase IIb Mesothelioma Trial. Silas Inman ...AstraZeneca has not yet released any data from the study.
AstraZeneca Clinical Trials Website
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=13


This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be ...




Page navigation
1 2 3 4 5 6 7 8 9 10 Next